- Aubrai launched on Base to tackle science funding issues.
- Involves key players like Aubrey de Grey.
- Innovative tokenomics could impact scientific research funding.
Aubrai, a decentralized science AI, launched on Base to address science funding challenges, co-developed by VitaDAO and Bio Protocol, with support from Aubrey de Grey’s LEV Foundation.
The launch signifies a shift in funding mechanisms for scientific research, boosting market interest in decentralized science tokens, as indicated by BIO token’s recent value surge.
Aubrai, a decentralized science (DeSci) AI agent, has been launched on the Base network. Developed by VitaDAO and Bio Protocol, it aims to tackle funding issues in scientific research, particularly focusing on the “valley of death” in longevity studies.
Key players include Dr. Aubrey de Grey, a prominent biomedical gerontologist, VitaDAO, and Bio Protocol. Aubrai operates as a decentralized scientific agent integrating unpublished data, helping in experimental design and safeguarding trade secrets.
In the words of Aubrey de Grey, Founder, LEV Foundation, “Aubrai will finally allow us to test large-scale multi-target rejuvenation and unlock new experiments that would otherwise languish unfunded or unproven.”
Aubrai’s launch is expected to influence the industries and markets involved in longevity and biotech research. The introduction of the AUBRAI token and its distribution strategy could reshape funding mechanisms for scientific endeavors.
Financial implications include the AUBRAI token sale and partnerships with firms like VitaDAO. Industry observers speculate increased attention and potential financial shifts driven by the new tokenomics model.
Potential regulatory outcomes hinge on wider acceptance and institutional interest in Aubrai. Technological outcomes could include enhanced integration of AI in research, with promising precedents set by similar decentralized protocols.
Tweet about this
